Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021
High Resolution Image Download MS PowerPoint Slide KRAS G12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRAS G12C, selective inhibition of KRAS G12D presents a significant challenge due to the requirement of inhibitors to bind KRAS G12D with high enough affinity to obviate the need for covalent interactions with the mutant KRAS protein. Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRAS G12D inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRAS G12D mutant xenograft mouse tumor model.
Cited by 737 works. doi:10.1021/acs.jmedchem.1c01688
Authors
- Xiaolun Wang
- James F. Blake
- Vickie Bowcut
- David M. Briere
- Andrew Calinisan
- Joshua R. Dahlke
- Jay B. Fell
- Robin J. Gunn
- Jill F. Hallin
- Jade Laguer
- J. David Lawson
- James Medwid
- Brad Newhouse
- Jacob M. O’Leary
- Peter Olson
- Spencer Pajk
- Lisa Rahbæk
References
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- Drugging the undruggable RAS: Mission Possible?
- A Comprehensive Survey of Ras Mutations in Cancer
- RAS Proteins and Their Regulators in Human Disease
- Unrolling the hydrogen bond properties of C–H···O interactions
- Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity
- Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
- The Frequency of Ras Mutations in Cancer
- Identification of the Clinical Development Candidate MRTX849 , a Covalent KRASG12C Inhibitor for the Treatment of Cancer
- Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors